Study evaluates the use of AI-supported medical coding module.
*** Monday, May 24, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST *** Most organizations deal with the vulnerabilities that exclusive point solutions create. Join industry leaders Oracle and IQVIA to understand how inclusivity and a flexible environment can help you employ new approaches faster, and the benefits of collaboration in today’s clinical trials ecosystem.*** On demand available after final airing until May 24, 2022 ***
Following the implement of new Drug Registration Regulation in July 2020, the clinical trial registration system will have some major changes in China.
What is next for DCTs after acceleration from COVID-19?
New requirements must be put in place to ensure data quality and integrity.
A first vaccine against this coronavirus could still take some time to develop, but mRNA vaccine platforms could offer an early breakthrough.
Biopharmaceutical sponsors should make urgent decisions now to plan for continued clinical research in the coming months.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
COVID spotlights the troubling disparity in clinical research representation. How can we remove these barriers?
Implementing disclosure and data transparency policies and procedures represents an opportunity for sponsors, rather than an obligation.
Sonja Wustrack, OM1, highlights a new clinical study automation platform to support critical data collection and real-world evidence.
RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.
Tufts Center for the Study of Drug Development and Biogen recently conducted a study to inform growing interest in improving diversity of clinical trial participation. The results of this research provide insights into increasing the community of minority investigators and study staff and presenting greater access to clinical trials among minority study volunteers.
Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.
The benefits of working with an institutional biosafety committee in CGT research.
Phesi and Tufts CSDD share results from research on operating practices that can be improved.
Approaching protocol design and operational planning with patient empathy.
Understanding the role of social determinants on clinical trial participation and trust.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
Improved diversity in clinical trials can be achieved by exploring opportunities for research in developing countries that have not historically participated in large-scale, industry-sponsored clinical trials.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.
A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia.
Amid CVS’ surprise exit from the clinical research space and the ensuing broader questions, study investigates the benefits of pharmacy chain involvement—along with the concerns and barriers to adoption.
Providing patients with more flexibility in how they choose to participate in trials.
Higher costs headline list of new challenges faced by CROs and sponsors.
Five strategies to reduce risk and achieve deadlines.